“This week, the medicines were not there”: What is at stake in the pandemic...
Earlier this week I listened to a testimony from a community worker at a maternity ward where HIV-positive women gave birth. 17 babies were...
Never say never – Why the High Income Countries that opted-out from the Art....
To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...
Medicines price transparency: Ground still left to cover
Parts of this blog were previously published in the Lancet Regional Health Europe
Secret medicines prices are hotly debated as European health systems struggle to...
Wrapping up 2025: A tumultuous year for global public health law & policy
The end of 2025, a tumultuous year for global public health, is here, and it’s time for the usually highly biased Medicines Law &...
Current drafts of the WHO Pandemic Accord lack a provision for access to knowhow/trade...
Negotiations are currently taking place at the World Health Organization (WHO) to conclude a new pandemic agreement by May 2024. The objective of the...
Time for new pharmaceutical-innovation models
The pharmaceutical industry is one of the most profitable on earth, expected to be worth $1.4 trillion by the end of 2020. Last year,...
Imagine if health and trade ministers would meet in one room this week
A earlier version of this commentary was published on 28 November 2021 by Barron's.
This is a time of missed opportunities. This week, trade ministers...
The new EU compulsory licensing regime needs to allow the export of medicines
Guest author Olga Gurgula is a Senior Lecturer in Intellectual Property Law at Brunel Law School, Brunel University London.
A war-weary Ukraine critically depends on the support of...
New reports offer evidence for extending the WTO Decision on TRIPS to Covid-19 therapeutics...
In February 2024, the 13th World Trade Organization (WTO) Ministerial Conference will take place. WTO Members are expected to decide whether to extend the...
FDA approval of injectable lenacapavir for Pre-Exposure Prophylaxis (PrEP) opens the road to ending...
On 18th June 2025, the US Food and Drug Administration (FDA) approved the use of long-acting antiretroviral medicine lenacapavir (LEN-LA), for the prevention of...